Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use.
about
Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197Factors contributing to the immunogenicity of meningococcal conjugate vaccinesImmune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization.Needle-Free Dermal Delivery of a Diphtheria Toxin CRM197 Mutant on Potassium-Doped Hydroxyapatite Microparticles.Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriersChemical synthesis of the outer core oligosaccharide of Escherichia coli R3 and immunological evaluation.Cross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sitesEnhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide.Immune approaches for the prevention of breast milk transmission of HIV-1.Preclinical evaluations of peptide-conjugate vaccines targeting the antigenic domain-2 of glycoprotein B of human cytomegalovirus.Immunogenicity in mice and non-human primates of the Group A Streptococcal J8 peptide vaccine candidate conjugated to CRM197.A modification-specific peptide-based immunization approach using CRM197 carrier protein: Development of a selective vaccine against pyroglutamate Aβ peptides.CRM197 in Combination With shRNA Interference of VCAM-1 Displays Enhanced Inhibitory Effects on Human Glioblastoma Cells.Immunogenicity and efficacy of a rationally designed vaccine against vascular endothelial growth factor in mouse solid tumor models.A semi-synthetic glycoconjugate vaccine candidate for carbapenem-resistant Klebsiella pneumoniae.Synthesis of multivalent glycopeptide conjugates that mimic an HIV epitope.Pentapeptide commonality between Corynebacterium diphtheriae toxin and the Homo sapiens proteome.Co-expression of sulphydryl oxidase and protein disulphide isomerase in Escherichia coli allows for production of soluble CRM197.Protein-protein conjugate nanoparticles for malaria antigen delivery and enhanced immunogenicity.Molecular Cloning, Structural Modeling and the Production of Soluble Triple-Mutated Diphtheria Toxoid (K51E/G52E/E148K) Co-expressed with Molecular Chaperones in Recombinant Escherichia coli.An antibacterial vaccination strategy based on a glycoconjugate containing the core lipopolysaccharide tetrasaccharide Hep2Kdo2.High level accumulation of soluble diphtheria toxin mutant (CRM197) with co-expression of chaperones in recombinant Escherichia coli.A Semi-Synthetic Glycoconjugate Vaccine Candidate for Carbapenem-Resistant Klebsiella pneumoniaeIntracellular trafficking of diphtheria toxin and its mutated form, CRM197, in the endocytic pathwayEfficient recovery of recombinant CRM197 expressed as inclusion bodies in E.coliStructural and immunological characterization of derived recombinant CRM protein used as carrier in conjugate vaccines
P2860
Q27678104-E10A346C-4107-4B09-B495-ED88DF4401E2Q28828544-37275D47-6B67-4000-9F97-0128DBAF8F4CQ34389901-AA6BC9A1-B0D1-4EB9-AB9B-7E1D57C4A23BQ35548057-6AE22E59-717B-4B1E-95DC-A910312BF0EBQ35756201-3FD68441-E77F-439C-8CFF-E8A751D346B8Q35783024-7CE1D8E1-C571-42D0-B058-AA1A9FF2705BQ35913681-9F404504-A792-432E-BAF9-AF9502DBC1BEQ36276014-E4CCE7A3-5A6C-4034-8AC9-3AB35E3C89F3Q37006608-CF386D39-FBD6-4A5B-88E5-A71D7F73D8B8Q37197051-6E326BE6-1452-473E-AB9A-7B70836E8474Q37478261-903B18E6-A807-4B39-B769-B25787D20AEFQ37604055-8F40363D-B19F-41D3-B2A1-850840BD3C0DQ38958467-3B6EADBF-1C53-422C-82A1-63BA67DCDB3BQ39165919-B6925583-97FB-418C-AD81-0C94B4512A1CQ40090364-F7799D49-B721-451E-AB92-5F9673E35525Q41835711-6A0868D8-D3FD-42C5-993E-D716DAB9BD1BQ46696206-51CFA667-4A7F-4EA2-94B4-6453F7CEA505Q46911551-AC0894F5-804C-476E-9435-CCB7B1CAF1D2Q47251697-6CE62E4E-445C-4F12-834B-580344C7CAF4Q48096971-FB78BE5F-08F3-4175-966C-60645531ED61Q50878644-C267AE32-88FA-463A-B738-026A71286C1DQ51411718-74B23745-E122-4BE8-9E59-4EF326E2041BQ57394794-512D5F9A-2158-4F72-A840-BDEFCA0AE866Q58131485-F368694F-4993-40C9-A2B5-89D77661C2C9Q58358482-EB3A3AD3-1B29-4F83-8AE9-E6D6570FE6E5Q58699527-59366797-30D0-4056-8683-985641A40A6E
P2860
Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Overview of the development and current use of CRM
@nl
Overview of the development an ...... te vaccines for pediatric use.
@ast
Overview of the development an ...... te vaccines for pediatric use.
@en
type
label
Overview of the development and current use of CRM
@nl
Overview of the development an ...... te vaccines for pediatric use.
@ast
Overview of the development an ...... te vaccines for pediatric use.
@en
prefLabel
Overview of the development and current use of CRM
@nl
Overview of the development an ...... te vaccines for pediatric use.
@ast
Overview of the development an ...... te vaccines for pediatric use.
@en
P1433
P1476
Overview of the development an ...... te vaccines for pediatric use.
@en
P2093
Henry R Shinefield
P304
P356
10.1016/J.VACCINE.2010.04.072
P407
P577
2010-05-07T00:00:00Z